Measuring Peripheral Arthritis, Enthesitis, Dactylitis and Patient Impact
Use DAPSA44 for its intended peripheral arthritis domain and complement it with enthesis, dactylitis, organ and patient-impact assessments.
On this page
Measurement should describe the decision
A reproducible score is valuable because it makes change visible. It becomes misleading when its domain is forgotten. Peripheral SpA can involve arthritis, enthesitis, dactylitis, axial disease and extra-musculoskeletal conditions. No single joint-oriented composite captures all of that. Choose an instrument for the problem being followed, then record the important domains it does not cover.
Before treatment, define both an inflammatory target and a patient-valued target. “Fewer swollen joints” and “able to walk through the workday” are related but different outcomes. Their disagreement at follow-up is useful information, not a failure of measurement.
Joint counts: name the examination
Record swollen and tender joints separately with the specified count system. A 66/68-joint assessment and a 44-joint assessment have different coverage. The same numeric result does not necessarily represent the same disease burden. A short count that omits the feet can miss important peripheral activity.
Examination technique and attribution matter. Distinguish tenderness from swelling, bony enlargement from synovitis, and a joint lesion from nearby tendon pathology. For serial assessments, use a consistent approach and record uncertainty at individual sites. Keep the actual locations available: a composite can hide the difference between two newly swollen ankles and two persistently tender finger joints.
ASAS-SPARADISE: a current published development
ASAS-SPARADISE selected DAPSA44 for disease activity related to peripheral arthritis in axSpA/pSpA clinical research. The main recommendation was published online in Annals of the Rheumatic Diseases on July 6, 2026. [1] It should no longer be described merely as ongoing work or a congress proposal.
The supporting comparative analysis used individual data from 13 randomized trials, including axial trials restricted to participants with peripheral arthritis and peripheral SpA trials. Composite measures generally performed better than single-item measures, with DAPSA44 showing consistent measurement properties. That analysis was published in September 2026. [2] These are measurement findings; they do not demonstrate that a DAPSA44-directed prescribing strategy improves every clinical outcome.
How DAPSA44 is calculated
The official ASAS implementation uses:
DAPSA44 = 1.3 × tender joint count (44) + 1.3 × swollen joint count (44) + patient joint pain (0–10) + patient global assessment (0–10) + CRP (mg/dL). [3]
The factor is applied to each 44-joint count. CRP reported in mg/L must be divided by 10 before entering a formula that expects mg/dL. Do not substitute a 28-joint count or omit the conversion while retaining the DAPSA44 name. The official calculator handles the stated laboratory unit and links the instrument’s source publications.
For an illustrative calculation, tender count 3, swollen count 2, pain 4, global 3 and CRP 10 mg/L give 1.3 × 3 + 1.3 × 2 + 4 + 3 + 1 = 14.5. This example teaches units and arithmetic; it is not a treatment recommendation. Retain the five input values with the total so a later reader can understand what drove the score.
Interpretation has limits
The ASAS calculator displays established DAPSA activity bands: remission at 4 or below, low above 4 through 14, moderate above 14 through 28, and high above 28. [3] A band is a description under that instrument. It does not certify remission of enthesitis, dactylitis, axial disease, psoriasis, IBD or uveitis.
DAPSA44 is not numerically interchangeable with original DAPSA calculated from full joint counts. Keep the instrument name visible when comparing visits or studies. A change in count coverage should not be concealed as a biological trend. Missing CRP is missing information; silently entering zero creates an apparently complete result that was never measured.
Enthesitis: standardize sites and preserve context
Clinical indices such as the Leeds Enthesitis Index count tenderness at defined sites. LEI was developed in PsA; other indices have different anatomical coverage and histories. [4] Use one consistently, add the clinically important sites it omits, and describe uncertainty about inflammatory attribution. A score records what the examination found, not a definitive mechanism for each tender location.
Ultrasound can complement the examination when discordance matters. The published DEUS Enthesitis Index combines clinical and ultrasound findings in axSpA/PsA and remains a distinct assessment approach with its own validation context. [5] It should not be presented as a universal replacement for clinical assessment or as an established treatment-escalation rule for non-psoriatic pSpA.
Dactylitis: more than a joint count
Record affected digits, tenderness and whether enlargement is currently inflammatory or residual. The Leeds Dactylitis Index was developed to quantify digit swelling and tenderness in PsA. [6] In routine care, a consistently recorded digit count with a clear description may be more informative than an inconsistently performed elaborate measure.
A dactylitic digit can impair grip, footwear and walking even when the joint composite is relatively low. Follow the same digit over time and distinguish improvements in pain, swelling and function. Do not infer whole-digit resolution merely because the tender joint count improved.
Patient impact belongs alongside activity
Measure pain and global assessment, but ask what they mean in this patient. Fatigue, poor sleep, work demands, structural damage and noninflammatory pain may influence responses. These are clinically important and deserve treatment; they do not automatically establish uncontrolled synovitis.
Choose a practical functional outcome, such as walking distance, ability to stand, hand use or a task that matters to the patient. Use validated functional or impact instruments where appropriate and keep wording and recall periods consistent. Patient and clinician assessments may diverge because they are observing different aspects of disease, not because one participant is necessarily mistaken.
A minimum longitudinal dataset
| Domain | Record at each meaningful review | Interpretation safeguard |
|---|---|---|
| Arthritis | Named joint counts, sites and DAPSA44 components when used | Check coverage and CRP units. |
| Entheses | Specified clinical index plus important additional sites | Tenderness is not uniquely inflammatory. |
| Dactylitis | Digits, tenderness and swelling | Residual enlargement differs from active inflammation. |
| Other domains | Axial, skin/nail, bowel and eye status | A joint score does not represent these domains. |
| Impact and safety | Function, patient priority, adverse effects and adherence | Improved activity may not resolve every limitation. |
When a number changes, inspect its components and the patient’s experience before changing therapy. The most useful measurement system creates a faithful longitudinal record and makes discordance easier to investigate. It does not turn multidomain care into a single automatic threshold.
Evidence in context
Source status checked October 6, 2026. Population applicability and publication maturity are separate judgments.
Scrollable evidence table
| Source | Population and phenotype | Design and status | Applicability | Clinical implication | Important limitation | Last checked |
|---|---|---|---|---|---|---|
| ASAS-SPARADISE [1] | AxSpA/pSpA with peripheral arthritis | Instrument-selection project; peer-reviewed July 2026 | Peripheral arthritis research | DAPSA44 endorsed for this domain | Not a universal multidomain score or prescribing algorithm | 2026-10-06 |
| 13-trial analysis [2] | Axial trials with arthritis subgroup plus pSpA trials | Secondary measurement analysis; peer-reviewed September 2026 | Mixed relevant trial populations | Composites outperform some single measures | Trial populations and existing available measures | 2026-10-06 |
| Official DAPSA44 implementation [3] | 44-joint examination and patient/lab inputs | Official implementation linked to peer-reviewed development | Correct computation | Use 1.3 factors and CRP mg/dL | Activity bands do not certify all-domain remission | 2026-10-06 |
| LEI [4] | PsA | Instrument development; peer-reviewed | PsA-derived enthesis assessment | Standardized tenderness sites | Limited site coverage; pain mechanisms can confound | 2026-10-06 |
| DEI [5] | AxSpA and PsA | Cross-sectional index development; peer-reviewed | Mixed SpA assessment | Combines clinical and ultrasound information | Further longitudinal/strategy validation needed | 2026-10-06 |
| Dactylitis instrument [6] | PsA | Instrument development; peer-reviewed | PsA-derived domain measure | Quantifies digit swelling and tenderness | Does not establish diagnosis or overall disease activity | 2026-10-06 |
Sources
- Ramiro et al. Instrument selection for peripheral arthritis: ASAS-SPARADISE (2026)
- Capelusnik et al. Measurement properties in 13 randomized trials (2026)
- ASAS. Official DAPSA44 calculator and source publications
- Healy and Helliwell. Leeds Enthesitis Index development (2008)
- Di Matteo et al. DEUS Enthesitis Index (2025)
- Helliwell et al. Development of a dactylitis assessment tool (2005)